

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/005,073
Filing Date	December 7, 2001
First Named Inventor	Anthony Jevnikar et al.
Examiner Name	GERALD R EWOLDT
Attorney Docket No.	1024916-000011

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

¹Enter Office that issued the document, by the two-letter code.

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	MAGEE et al., "A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients," <u>Clin. Transplant</u> , 2008, vol. 22, no. 6, pp. 754-759, PubMed (PMID: 18647327) (Abstract).
	ERGUN-LONGMIRE et al. "Oral Insulin Therapy to Prevent Progression of Immune-Mediated (Type I) Diabetes," <u>Ann. N.Y. Acad. Sci.</u> , 2004, vol. 1029, pp. 260-277, New York Academy of Sciences, New York, New York.
	"2005 KFOC Medal for Research Excellence", Published on the Kidney Foundation of Canada Website., 2005.
	"Plantigen, Dow AgroSciences Announce Collaboration:", Published in Plants for Health Plantigen, Inc., in London Ontario on June 21, 2003.

Examiner Signature _____ Date Considered _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.